[go: up one dir, main page]

AU2001273515A1 - Azolidines as beta-3 adrenergic receptor agonists - Google Patents

Azolidines as beta-3 adrenergic receptor agonists

Info

Publication number
AU2001273515A1
AU2001273515A1 AU2001273515A AU7351501A AU2001273515A1 AU 2001273515 A1 AU2001273515 A1 AU 2001273515A1 AU 2001273515 A AU2001273515 A AU 2001273515A AU 7351501 A AU7351501 A AU 7351501A AU 2001273515 A1 AU2001273515 A1 AU 2001273515A1
Authority
AU
Australia
Prior art keywords
azolidines
beta
receptor agonists
adrenergic receptor
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273515A
Inventor
Iwan Gunawan
Elwood Eugene Largis
Zenan Li
Michael Sotirios Malamas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001273515A1 publication Critical patent/AU2001273515A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001273515A 2000-07-17 2001-07-16 Azolidines as beta-3 adrenergic receptor agonists Abandoned AU2001273515A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21870600P 2000-07-17 2000-07-17
US60218706 2000-07-17
PCT/US2001/022408 WO2002006258A1 (en) 2000-07-17 2001-07-16 Azolidines as beta-3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
AU2001273515A1 true AU2001273515A1 (en) 2002-01-30

Family

ID=22816152

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273515A Abandoned AU2001273515A1 (en) 2000-07-17 2001-07-16 Azolidines as beta-3 adrenergic receptor agonists

Country Status (3)

Country Link
US (2) US6465501B2 (en)
AU (1) AU2001273515A1 (en)
WO (1) WO2002006258A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
CZ20031012A3 (en) 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
EP1430043A1 (en) 2001-09-14 2004-06-23 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
JPWO2003033468A1 (en) * 2001-10-17 2005-02-03 株式会社カネカ Method for producing (S) -α-halomethylpyridine methanol derivative
WO2003072547A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. PROCESSES AND INTERMEDIATES USEFUL IN PREPARING β3-ADRENERGIC RECEPTOR AGONISTS
WO2003072573A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
US20050055952A1 (en) * 2003-09-03 2005-03-17 Mcgonigal Todd Adjustable framing stud spacing means
ES2289691T3 (en) 2004-01-22 2008-02-01 Pfizer, Inc. DERIVATIVES OF SULFONAMIDE FOR THE TREATMENT OF DISEASES.
OA13362A (en) 2004-01-22 2007-04-13 Pfizer Sulfonamide derivatives for the treatment of diseases.
US7959645B2 (en) * 2004-11-03 2011-06-14 Boston Scientific Scimed, Inc. Retrievable vena cava filter
ZA200803226B (en) * 2005-10-13 2009-11-25 Orchid Res Lab Ltd Heterocyclic Compounds as Pstat3/IL-6 Inhibitors
US7557095B2 (en) * 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
CN103232368B (en) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 A kind of synthetic method of (R)-4-nitrophenethyl-(2-hydroxyl-2-styroyl)-t-butyl carbamate
CN103232352B (en) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (R)-4-(2-(2-hydroxyl-2-phenylethylamine base) ethyl) anilino carboxylate
CN106083758B (en) * 2016-06-20 2018-08-21 河南师范大学 A kind of high-efficiency synthesis method of Mirabegron
EP3696177A1 (en) 2019-02-12 2020-08-19 Basf Se Heterocyclic compounds for the control of invertebrate pests
CN113816864B (en) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 Preparation method of (R) -2-hydroxy-N- [2- (4-aminophenyl) ethyl ] -2-phenethylamine

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
EP0089154A3 (en) 1982-03-12 1984-08-08 Beecham Group Plc Ethanolamine derivatives, their preparation and use in pharmaceutical compositions
GB2163150B (en) 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
US4813998A (en) 1986-02-27 1989-03-21 Janssen Pharmaceutica N.V. Herbicidal 1H-imidazole-5-carboxylic acid derivatives
EP0449261A3 (en) 1990-03-29 1992-02-26 Kabushiki Kaisha Toshiba Resin composition for an optical disc and an optical disc using it
ES2139633T3 (en) 1992-08-31 2000-02-16 Sankyo Co DERIVATIVES OF OXAZOLIDINE WITH ANTI-DIABETIC AND ANTI-OBESITY PROPERTIES, ITS PREPARATION AND ITS THERAPEUTIC USE.
US5998452A (en) 1993-06-23 1999-12-07 Chugai Seiyaku Kabushiki Kaisha Benzene derivatives, compositions and methods for treating ischemic diseases
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
TW363959B (en) 1994-03-23 1999-07-11 Sankyo Co Thiazolidine and oxazolidine derivatives, their preparation and their medical use
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5741789A (en) 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5789402A (en) 1995-01-17 1998-08-04 Eli Lilly Company Compounds having effects on serotonin-related systems
US5614523A (en) 1995-01-17 1997-03-25 Eli Lilly And Company Compounds having effects on serotonin-related systems
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
AU715216B2 (en) 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
AU712057B2 (en) 1996-06-07 1999-10-28 Merck & Co., Inc. Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity
JP2000514041A (en) 1996-07-26 2000-10-24 ドクター・レディーズ・リサーチ・ファウンデーション Thiazolidinedione compounds having anti-diabetic, hypolipidemic and anti-hypertensive properties, their preparation, and their pharmaceutical compositions
WO1998022480A1 (en) 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
CA2278739A1 (en) 1997-01-28 1998-07-30 Emma R. Parmee Thiazole benzenesulfonamides as .beta.3 agonists for the treatment of diabetes and obesity
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
EP1028111B1 (en) 1997-10-17 2004-05-12 Yamanouchi Pharmaceutical Co. Ltd. Amide derivatives or salts thereof
FR2780057B1 (en) 1998-06-18 2002-09-13 Sanofi Sa PHENOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6214842B1 (en) 1999-05-12 2001-04-10 Michael S. Malamas Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
FR2798126B1 (en) 1999-09-08 2001-10-19 Sanofi Synthelabo HETEROARYLOXYPROPANOLAMINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE60033964T2 (en) 1999-12-17 2007-11-29 Sanofi-Aventis PHENOXYPROPANOLAMINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE
FR2802533B1 (en) 1999-12-17 2002-02-15 Sanofi Synthelabo PHENOXYPROPANOLAMINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2002006258A1 (en) 2002-01-24
US6569873B2 (en) 2003-05-27
US6465501B2 (en) 2002-10-15
US20020032222A1 (en) 2002-03-14
US20030055079A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
AU2002222929A1 (en) Cyclylamine sulfonamides as beta-3 adrenergic receptor agonists
AU2002222932A1 (en) N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists
AU2001280568A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
AU2001273515A1 (en) Azolidines as beta-3 adrenergic receptor agonists
IL154911A0 (en) Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
AU2002222930A1 (en) Cyclic amine phenyl beta-3 adrenergic receptor agonists
AU2371601A (en) Hydrogels
AU2001273508A1 (en) Heterocyclic beta-3 adrenergic receptor agonists
AU2001273542A1 (en) 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
AU2001274593A1 (en) Cold-setting composition
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU2001259051A1 (en) Piperidyindoles as serotonin receptor ligands
AU2001247227A1 (en) 2-thioether a2a receptor agonists
AU2001278377A1 (en) Wiper arm
AU2002223434A1 (en) Wiper arm
AU2001230594A1 (en) Novel scavenger receptors
AU2001223882A1 (en) Receptor
AU2001273501A1 (en) Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
AU4045101A (en) Wiper arm
AU2001272352A1 (en) Wiper board fixture
AUPQ563400A0 (en) Novel receptor
AU2001276326A1 (en) Wiper
AU2001271933A1 (en) Alpha,alpha-dibromo-alpha-chloro-acetophenones as synthons
AU2002346030A1 (en) Novel receptors
WO2002077001A9 (en) Novel receptors